50
Management of Well Differentiated Thyroid Cancer Vivek Ramarathnam, M.D. SIU- Otolaryngology Grand Rounds 9/1/2005

09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Embed Size (px)

Citation preview

Page 1: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Management of Well Differentiated Thyroid Cancer

Vivek Ramarathnam, M.D.

SIU- Otolaryngology

Grand Rounds

9/1/2005

Page 2: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Nodules

Between 4-7% of individuals in US have palpable thyroid nodules

More common in women Increase in frequency with age Fewer than 10% of solitary nodules are

malignant- Papillary (75%)- Follicular (15%)

Page 3: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Carcinoma

1.5% of all newly diagnosed cancers Number increasing over last 25 years;

4.8 to 8.0 cases per 100,000 Female predominance (11.7 female to 4.2

male cases/100,000 Death rate 0.5 cases per 100,000

Page 4: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Nodules and Carcinoma Rates

Rates of carcinoma in a single nodule: 5-17%

Rates of carcinoma in multinodular patients: 5-13%

Page 5: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Risk Factors for Malignancy

Prior irradiation Family history Male sex Nodules in individuals <15, >45 Symptoms of invasiveness: development of

hoarseness, progressive dyshagia, or dyspnea

Page 6: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Physical Examination

Pulse rate, Blood Pressure Neck Lymphadenopathy Deviation of Trachea Palpation of Thyroid gland(Size, consistency, mobility, presence or

absence of tenderness, multinodularity) Attention of thyroid mass to surrounding

anatomy

Page 7: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Preoperative Evaluation

Individuals with symptoms potentially of invasive carcinoma- dysphonia, dysphagia, or stridor

Flexible laryngoscopy MRI allows soft tissue evaluation (cervical

esophageal invasion) CT, readily available, iodinated contrast used can

delay the use of RAI postoperatively 4-6 weeks Selected patients, panendoscopy

Page 8: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Picture

Page 9: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Anatomy

Arteries- Paired arteries, superior, inferior arteries

Venous drainage- parallels arterial drainage, superior thyroid veins drain into internal jugular vein, inferior thyroid veins to brachiocephalics

Lymphatics- intraglandular lymphatic network, paratracheal, upper, mid, and lower jugular nodes

Page 10: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Hormone Physiology

Growth- hormones work in bone formation CNS- brain maturation Basal metabolic rate Cardiovascular and respiratory systems Metabolic effects

Page 11: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Histology

Page 12: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Thyroid Hormone Regulation

TSH stimulates both

iodine uptake and its organification

Page 13: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Management steps with a Thyroid Nodule

1. TSH level

- 95% of all nodules are hypofunctional (cold)

2. If TSH normal, obtain a ultrasound and perform FNA

- if firm and palpable FNA can be performed without image guidance

Page 14: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Ultrasound Imaging and Nodules

US reports thyroid size and appearance, 3D description of specific nodules, presence of paratracheal nodes, and evidence of invasive qualities.

Useful in individuals undergoing FNA and have difficult lesions to palpate.

Also beneficial in complex cysts, and nodules with questionable multinodularity

Page 15: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Management steps with a Thyroid Nodule

If TSH high, treat with thyroid hormone replacement and FNA when patient is euthyroid

TSH level low; may have hyperfunctioning nodule and should be evaluated with thyroid scan. Low likelihood of malignancy

Page 16: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Evaluation of solitary nodule

FNA (fine needle aspiration)

4 types of interpretations:

1) Benign

2) Malignant

3) Suspicious for follicular or Hurthle cell tumor

4) Insufficient for diagnosis

Page 17: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Overview of Nodule workup

Page 18: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Case Presentation

22 female referred for enlarging thyroid mass Right lobe of thyroid. Last year 2.8 cm and now 3.4 cm in greatest diameter. Complex mass described per US report. Otherwise asymptomatic. Mother- hyperthyroid. Medications: Effexor XR, Ortho patch

FNA- Cellular follicular lesion

Page 19: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Papillary Carcinoma

Page 20: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Follicular Carcinoma

Page 21: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Fine needle aspiration

Procedure requires skill by operator, as well as by cytopathologist

Even in skilled hands, approximately 10% of biopsy findings nondiagnostic

Sensitivity 92%, Specificity- 91-97.5%

Page 22: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Findings on FNA

Benign finding- Followed serially by US

If nodule has increased in size ~15%, repeat FNA should be performed

Follicular neoplasm- 80% of these nodules are benign, 20% represent thyroid carcinoma

Papillary carcinoma- accuracy of FNA approaches 100%

Page 23: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Fine needle aspiration

Suspicious for follicular or Hurthle cell tumor

Diagnosis of follicular of Hurthle cell tumor from follicular carcinoma or Hurthle cell carcinoma requires presence or absence of capsular or vascular invasion seen on histologic examination of surgical specimens

Follicular and Hurthle cell tumors diagnosed by FNA have malignancy rate of 10-20%

Page 24: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Case Presentation

Pt underwent Right lobectomy with isthmusectomy

Frozen section- Follicular neoplasm Final pathology- Follicular adenoma

Page 25: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Management of FNA results

Follicular neoplasm- Thyroid lobectomy, allow histiopathologic

diagnosis to dictate need for total- Serial US, TSH suppression, repeat FNA- Plan for lobectomy with frozen section, if

reveals follicular variant of papillary, perform total - Perform total thyroidectomy

Page 26: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Staging

Page 27: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Staging

Page 28: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

5 year survival rates

Papillary Cancer Follicular Cancer

Stage 1 100% 100%

Stage 2 100% 100%

Stage 3 95.8% 79.4%

Stage 4 45.3% 47.1%

Page 29: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Risk Analysis

AGES (age, grade, extent, size) AMES (age, metastases (distant), extent,

size) MACIS (metastasis, patient age,

completeness of resection, local invasion, and tumor size)

Page 30: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

AGES

Hay ID, et al. 61st American Thyroid Association Annual Meeting 1986

Papillary CAN= 860Age= 0.5 x ageGrade2 = 1Grade3-4 =3Extrathyroidal=1E(distant)= 3Size= 0.2 x cm

Page 31: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Hay ID, et al.

Page 32: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Surgical Management

Wein, RO, Weber RS, Contemporary Management of Differentiated Thyroid Carcinoma. Otolaryngol Clin N Am 2005

“ Surgery therapy for the majority of well-differentiated thyroid carcinomas should be tailored to the eradication of macroscopic disease while preserving the patient’s capacity for functional speech and swallowing and parathyroid preservation.”

Page 33: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Lobectomy vs. Total Thyroidectomy

Shaha AR, Shah JP, Loree TR Ann Surg Oncol 1997

Low risk patients need selective treatment Retrospective review of 1038 patients, 465

patients in low risk group, 403 patients papillary and 62 patients follicular

Median follow-up 20 years. No statistical difference in overall failure rate or local recurrence rate between lobectomy vs. total thyroidectomy

Page 34: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Reasons for Total Thyroidectomy

Hay ID et al. Surgery 1987

Removes not only the primary tumor but also microscopic contralateral disease ~80%

Prevents local recurrence (5-24%) or anaplastic (<1%) transformation in the contralateral lobe

Decreased need for 2nd operation with increased risk Thyroglobulin surveillance for recurrence Radioactive iodine scanning/therapy

Page 35: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Complications of Total Thyroidectomy

Hypoparathyroidism ~ 10% Recurrent laryngeal nerve paralysis ~1%

Page 36: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Sites of Invasive Spread

McCaffrey, TV et al. Mayo Clinic, 50-year experience. Head Neck 1994

Trachea 37%

Esophagus 21%

Recurrent laryngeal nerve 47%

Strap musculature 53%

Larynx 12%

Other structures 30%

Page 37: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Surgical Considerations

Tracheal involvement

- Window and sleeve resections

- Larger defects, sternocleidomastoid and pectoralis major myoperiosteal flaps over T-tubes

- Tracheal resection with re-anastomosis

Page 38: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Esophageal Invasion

Tends to invade only the outer muscular layers

Limited resection without intraluminal entry is posssible

When intraluminal invasion encountered, primary closure vs. free tissue transfer for larger resections

Page 39: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Recurrent laryngeal nerve

Falk SA, McCaffrey TV. Otolaryngol Head Neck Surg 1995

Retrospectively compared patients and noted that complete resection of tumor and nerve sacrifice offered no survival benefit over potentially incomplete resection of tumor and nerve preservation

Page 40: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Laryngeal Involvement

Vertical partial laryngectomy, unilateral disease

Supracricoid partial laryngectomy, extensive anterior invasion

Total laryngectomy, extensive laryngeal spread

Page 41: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Regional metastasis

Intraglandular lymphatics First nodal drainage paralaryngeal,

paratracheal, prelaryngeal nodes VI Second level of drainage II, III, IV, V Elective neck dissection in setting of papillary

CA will detect occult spread in 50% of patients; reported no added benefit on survival

Page 42: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Regional metastasis

Radiologic imaging for regional spread include US, CT, and MRI

US- most accurate when combined with FNA, Serial tests can evaluate changes in nodal size

Imaging criteria for CT/MRI: recurrent disease, clinical lymph node metastases, vocal cord paralysis, fixation of mass to adjacent structures, symptoms of upper aerodigestive involvement

Type of neck dissection dictated by extent of disease

Page 43: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Neck dissection

Ferlito A., Pellitteri PK, Robbins KT et al. Review article. Acta Otolaryngol 2002

Selective dissection for extension of tumor noted, direct involvement of non-lymphatic structures

In high risk patients (male >45, with large 4cm cancer) recommend ipsilateral paratracheal node dissection given highest risk of containing metastases

Low risk, palpate region if no enlarged lymph nodes, elective neck dissection not carried out

Page 44: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Postoperative treatment

Radioactive iodine ablation decreases the local recurrence and mortality rates in patients with stage 2 and stage 3 well-differentiated thyroid carcinoma

Use of postoperative RAI and thyroid hormone supression has been advocated for patients with tumors > 1.5 cm

Page 45: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Long term potential complications of Thyrotropin (TSH) Suppression

Increased bone loss, particularly in postmenopausal women

Hyperthyroidism Cardiac hypertrophy Cardiac arrythmias

Page 46: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Radioactive Iodine Side Effects

Radiation thyroiditis (when large remnant present), sialoadenitis, taste dysfunction, nausea

Page 47: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Postoperative Treatments

Thyroglobulin levels in the absence of normal

thyroid tissue, is a sensitive and specific marker for the presence of thyroid cancer

Ideally this assay should be performed when the thyrotropin (TSH) level is elevated

Recombinant human TSH Ongoing clinical surveillance

Page 48: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Postoperative followup

Woodrum DT, Gauger PG Journal of Surgical Oncology 2005

Page 49: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Other Therapies

Not first line therapy, external beam radiation may have a role in treatment of non-RAI avid tumors, gross residual tumor, or unresectable disease

Also clinical trials involving gene therapy and tumor redifferentiation research

Page 50: 09 01 05 Entgr Management Of Well Differentiated Thyroid Cancer

Conclusions

Strategy for Thyroid Nodules Understanding prognosis- low, intermediate,

high risk Total Thyroidectomy and Radioiodine

Ablation for High Risk In the future, have more effective screening

and therapies